Characteristics of Advanced Parkinson's Disease Patients Who Discontinued During Conversion to IPX066, Extended-Release Carbidopa-Levodopa

被引：0
|
作者：
Kreitzman, David [2 ]
Dhall, Rohit [3 ]
Kell, Sherron [1 ]
Khanna, Sarita [1 ]
Gupta, Suneel [1 ]
机构：
[1] Impax Labs Inc, Hayward, CA USA
[2] Parkinsons Dis & Movement Disorders Ctr Long Isl, Commack, NY USA
[3] Parkinsons Inst & Clin Ctr, Sunnyvale, CA USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.339
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson's disease patients: Dosing patterns
    Morgan, J.
    Stacy, M.
    Rubens, R.
    Khanna, S.
    Gupta, S.
    MOVEMENT DISORDERS, 2016, 31 : S659 - S659
  • [2] Dosing Patterns During Conversion to IPX066, Extended-Release Carbidopa-Levodopa, from Other Carbidopa-Levodopa Formulations in Advanced Parkinson's Disease Patients
    Morgan, John
    Stacy, Mark
    Rubens, Robert
    Khanna, Sarita
    Gupta, Suneel
    NEUROLOGY, 2016, 86
  • [3] Efficacy of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease patients with troublesome dyskinesia
    Dhall, R.
    Struck, L.
    Rubens, R.
    Shah, V.
    Gupta, S.
    MOVEMENT DISORDERS, 2015, 30 : S79 - S80
  • [4] Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease
    Mueller, Thomas
    Moehr, Jan-Dominique
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (18) : 2063 - 2071
  • [5] IPX066: a novel carbidopa-levodopa extended-release formulation
    Hauser, Robert A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (02) : 133 - 140
  • [6] Efficacy of IPX066, Extended-Release Carbidopa-Levodopa: Subgroup Analysis in Advanced Parkinson's Disease Patients with Troublesome Dyskinesia
    Dhall, Rohit
    Struck, Lynn
    Rubens, Robert
    Khanna, Sarita
    Gupta, Suneel
    NEUROLOGY, 2016, 86
  • [7] Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease
    Tetrud, James
    Nausieda, Paul
    Kreitzman, David
    Liang, Grace S.
    Nieves, Anette
    Duker, Andrew P.
    Hauser, Robert A.
    Farbman, Eric S.
    Ellenbogen, Aaron
    Hsu, Ann
    Kell, Sherron
    Khanna, Sarita
    Rubens, Robert
    Gupta, Suneel
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 373 : 116 - 123
  • [8] The influence of baseline disease severity on the efficacy of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease
    Espay, A. J.
    Liang, G.
    Sharma, K.
    Rubens, R.
    MOVEMENT DISORDERS, 2015, 30 : S81 - S81
  • [9] Efficacy and Safety of IPX066, a Carbidopa-Levodopa, Extended-Release Formulation, in Early Parkinson's Disease
    Pahwa, Rajesh
    Elllenbogen, Aaron
    Kell, Sherron
    O'Conell, Martin
    Hauser, Robert
    Fahn, Stanley
    Jankovic, Joseph
    Pourcher, Emmanuelle
    Hsu, Ann
    Gupta, Suneel
    ANNALS OF NEUROLOGY, 2013, 74 : S47 - S47
  • [10] The influence of concomitant medication on the efficacy of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease
    LeWitt, P.
    Metman, L. Verhagen
    Rubens, R.
    Shah, V.
    Kell, S.
    Gupta, S.
    MOVEMENT DISORDERS, 2015, 30 : S100 - S100
12345